Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00527423 · ClinicalTrials.gov registry record · Phase 2
Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMD
A Phase 2 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 157
- Enrollment target
NCT00527423 is a Phase 2 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 157 participants.
The verdict
NCT00527423, a Phase 2 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 157 participants
- Enrollment target
Study Summary
Rollover study for subjects in prior VEGF Trap-Eye Phase I and II studies. Primary objective is to assess long-term safety and tolerability of continuing intravitreal treatment in subjects with wet age-related macular degeneration.
Interventions
- DRUG VEGF Trap Eye
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 157 participants |
| Start Date | 2007-08 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00527423
The ClinicalTrials.gov registry entry for NCT00527423 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 157 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VEGF Trap Eye is the first listed.
NCT00527423 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00527423 about?
NCT00527423 is a clinical study titled "Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMD". Rollover study for subjects in prior VEGF Trap-Eye Phase I and II studies. Primary objective is to assess long-term safety and tolerability of continuing intravitreal treatment in subjects with wet age-related macular degeneration.
What is the current status of trial NCT00527423?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 157 participants. The study started on 2007-08. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00527423?
The interventions under investigation include: VEGF Trap Eye (DRUG).
Who is sponsoring clinical trial NCT00527423?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.